EGFR alterations in cancer include mutations—for instance in non‐small cell lung cancer (NSCLC)—managed with tyrosine kinase inhibitors (TKIs), or overexpression (e.g., in colorectal cancer), often managed with monoclonal antibodies (mAbs). This evidence concerns the gene EGFR and cancer.